Nyxoah (NYXH) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nyxoah SA showcased positive outcomes at the International Surgical Sleep Society meeting from their DREAM study on the Genio implant for treating Obstructive Sleep Apnea (OSA), with significant reductions in Apnea-Hypopnea Index (AHI) and improvements in patients’ quality of life. Over 80% of participants achieved an AHI below 15 after 12 months, indicating effective management of OSA. The company is now moving towards FDA approval, marking a significant step in making Genio available in the US.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.